NCT00190736已完成4 期
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 440
- 试验地点
- 18
- 主要终点
- Atomoxetine administered orally, QD in the AM, from 25 mg/day to 100 mg/day for 6 months is superior to placebo in ADHD adults.
研究概览
简要总结
A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female patients with ADHD ages 18-
- •Patient must have ADHD symptoms that cause problem(s) in the home setting.
排除标准
- •Have failed to respond to an adequate trial of treatment with an ADHD stimulant medication, bupropion, or other nonstimulant medication.
- •Are taking any antipsychotic medication or mood stabilizers within 8 weeks of Visit 1
结局指标
主要结局
Atomoxetine administered orally, QD in the AM, from 25 mg/day to 100 mg/day for 6 months is superior to placebo in ADHD adults.
次要结局
- Atomoxetine administered QD in the AM, provides superior efficacy in the evenings compared with placebo in ADHD adults.
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity DisorderNCT00191295Eli Lilly and Company240
已完成
3 期
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/AdolescentsAttention Deficit Hyperactivity DisorderNCT00191659Eli Lilly and Company200
已完成
4 期
Evaluation of Continuous Symptom Treatment of ADHDAttention Deficit Hyperactivity DisorderNCT00486122Eli Lilly and Company282
已完成
4 期
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum DisorderAutistic DisorderAttention Deficit Disorder With HyperactivityNCT00380692Eli Lilly and Company97
已完成
4 期
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesAttention Deficit Hyperactivity DisorderNCT00510276Eli Lilly and Company445